-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab in Non-Small Cell Lung Cancer Drug Details: Zenocutuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Hypopharyngeal Cancer Drug Details: Petosemtamab (MCLA-158) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Oropharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Oropharyngeal Cancer Drug Details: Petosemtamab (MCLA-158) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Oral Cavity (Mouth) Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Oral Cavity (Mouth) Cancer Drug Details: Petosemtamab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Petosemtamab in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Petosemtamab in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Petosemtamab in Recurrent Head And Neck...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zenocutuzumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zenocutuzumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zenocutuzumab...
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s (Borneol + Edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (Borneol + Edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewSharing Economy – Thematic Intelligence
Sharing Economy Thematic Intelligence Report Overview The sharing economy is an economic system in which private individuals share assets and services, either free or for a charge often using a community-based online platform. Individuals can share assets such as clothes and toys or services such as household skills and insurance. The sharing economy is based on ideas of community as the world grows ever more interconnected. As the sharing economy model reaches maturity, market players are harnessing technologies such as...